Interim report January-September 2015: Increased organic growth

Third quarter:

  • Sales amounted to SEK 177 (125) million, corresponding to an increase of 41 percent in SEK. Sales growth was 29 percent in local currency. The acquisition of Vitrolife A/S (formerly Unisense FertiliTech A/S) contributed SEK 25 million to sales. Adjusted for this, sales growth amounted to 11 percent in local currency.
  • Operating income before depreciation and amortization (EBITDA) amounted to SEK 82 (49) million, corresponding to a margin of 46 (39) percent. Income was positively affected by the recovered additional purchase price for the acquisition of Cryo Innovation to the tune of SEK 17 million. Adjusted for this one-time item, EBITDA amounted to SEK 65 million, corresponding to a margin of 37 percent. Fluctuations in exchange rates had a positive effect of SEK 10 million on EBITDA.  
  • Net income amounted to SEK 52 (36) million, which gave earnings per share of SEK 2.41 (1.79).

January-September:

  • Sales amounted to SEK 523 (374) million, corresponding to an increase of 40 percent in SEK. Sales growth was 25 percent in local currency. The acquisition of Vitrolife A/S (formerly Unisense FertiliTech A/S) contributed SEK 79 million to sales. Adjusted for this, sales growth amounted to 6 percent in local currency.
  • Operating income before depreciation and amortization (EBITDA) amounted to SEK 198 (123) million, corresponding to a margin of 38 (33) percent. Income was positively affected by the recovered additional purchase price for the acquisition of Cryo Innovation to the tune of SEK 17 million. Adjusted for this one-time item, EBITDA amounted to SEK 181 million, corresponding to a margin of 35 percent. Fluctuations in exchange rates had a positive effect of SEK 30 million on EBITDA.  
  • Net income amounted to SEK 126 (81) million, which gave earnings per share of SEK 5.79 (4.07).

Gothenburg, November 5, 2015
VITROLIFE AB (publ)
Thomas Axelsson, CEO

Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14

Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on November 5, 2015 at 08:30 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

_________________________________________________________________________________________________________________

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes

Vitrolife has approximately 330 employees and the company's products are sold in almost 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The Vitrolife share is listed on NASDAQ OMX Stockholm, Mid Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/

Tags:

About Us

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets products for assisted reproduction. Vitrolife has about 370 employees and the company’s products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.

Subscribe

Documents & Links